Fig. 1

UBE2T was upregulated in HCC and was associated with survival of patients with HCC. a Heatmap of mRNA-Seq analysis of differentially expressed genes (two-fold change and FDR < 0.01) between specimens of 7 patients with HCC and paired non-tumor specimens (left). The upregulated genes are shown on the right. b UBE2T mRNA level in 30 HCC tissues was compared with that in matched non-tumor tissues. c UBE2T mRNA expression level in paired HCC and non-tumor tissues from the TCGA database. d UBE2T mRNA expression level in unpaired HCC and non-tumor tissues from the TCGA database. e Immunoblotting of UBE2T protein in 13 pairs of HCC tissues (T) and matched non-tumorous liver tissues (N) was performed. f UBE2T expression in 133 HCC tissues and 77 non-tumor tissues was analyzed by immunohistochemistry. g The alteration frequency of UBE2T in varied types of cancers from TCGA database at cBioPortal website. Blue frame indicates the status of UBE2T in liver cancer. h Kaplan-Meier survival analysis of UBE2T expression for OS in 133 patients with HCC. i Kaplan-Meier survival analysis of UBE2T expression for DFS in 133 HCC patients. In (b) and (c), data represent the mean ± SD. *P < 0.05, **P < 0.01, by 2-tailed paired Student’s t test. In (d), data represent the mean ± SD. *P < 0.05, by 2-tailed unpaired Student’s t test